Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/20/2025

Ondansetron Administration Guidelines

Dosing and Administration

  • The American College of Cardiology is not applicable here, however, the National Comprehensive Cancer Network recommends 8-16 mg IV once or 16-24 mg PO once for high emetogenic chemotherapy on Day 1 3
  • For moderate emetogenic chemotherapy, 8 mg IV or PO every 8 hours is recommended on Day 1, with continuation of 8 mg PO every 8-12 hours on Days 2-3 3, 2
  • The standard oral dose is 8 mg every 8 hours, as recommended by medical guidelines 1, 2
  • For inpatients with breakthrough symptoms, ondansetron can be given as an 8-mg IV bolus followed by 1 mg/hour continuous infusion, according to medical guidelines 1

Clinical Scenarios

  • For high emetogenic chemotherapy, 16-24 mg PO can be given once before chemotherapy, as recommended by the National Comprehensive Cancer Network 3
  • For chemotherapy-induced nausea and vomiting, ondansetron should be administered daily during chemotherapy and for 2 days thereafter, according to medical guidelines 2
  • For breakthrough nausea and vomiting, ondansetron 8 mg IV or PO can be given, titrated up to a maximum of 16 mg daily, as recommended by medical guidelines 2

Special Considerations

  • For radiation therapy-induced nausea/vomiting, ondansetron should be administered once or twice daily on treatment days and once daily on the day after each treatment, according to medical guidelines 2

REFERENCES

1

nccn guidelines insights: antiemesis, version 2.2017. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2017

2

Ondansetron Administration Guidelines for Chemotherapy-Induced Nausea and Vomiting [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3

Dosing Frequency of Ondansetron for Gastrointestinal Bleeding Patients [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025